Company

Euroimmun and IDS: Working together for the IDS i20

#bettertogether Last spring, IDS and Euroimmun launched the new random access instrument IDS i20. This new automation solution followed the random access instruments IDS-i10 and IDS-iSYS already established in the market. The device was developed based on IDS’ 50 years of expertise in laboratory automation – always focusing on maximum convenience for the users and reliability. For […]

Company

New e-mail addresses for all Euroimmun employees

Following the successful launch of our new design last summer, another change at Euroimmun and IDS takes place, which makes our affiliation to Revvity, Inc. more visible. As part of our strategic development, we are consolidating the technical systems of our three companies. This will enable us to provide an even better service thanks to

Company

What you know and trust – now with a new shine

Our new design is here!  Clearer, more modern, more international.   With our new design and visual language we have achieved a strong visual alignment with the corporate identity of Revvity, Inc. At the same time, we harmonized the visual appearance of the Euroimmun and IDS brands creating a new modernized look which visually reflects our shared identity and growing collaboration.  But what really counts remains the same: our

Unveiling of the new logo from Euroimmun
Company

What you know and trust – soon with a new shine

Euroimmun is modernizing its brand appearance Our company has undergone significant developments in recent years. This will now also be reflected in our visual appearance. At the ADLM in Chicago (July 27–31, 2025), we will show you our new, modernized look for the first time, underlining our innovative power and our international orientation. But, of

Products

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Press release, March 3rd 2025 Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s

Scroll to Top